Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients

BACKGROUND: Ketoconazole is a well-known CYP-17-targeted systemic treatment for castration-resistant prostate cancer (CRPC). However, most of the published data has been in the pre-chemotherapy setting; its efficacy in the post-chemotherapy setting has not been as widely described. Chemotherapy-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Ernest N., Beckett, Laurel A., Pan, Chong-Xian, Robles, Daniel, Suga, Jennifer M., Sands, Jacob M., Lara, Primo N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430382/
https://www.ncbi.nlm.nih.gov/pubmed/25667107
http://dx.doi.org/10.1038/pcan.2015.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430382/
https://www.ncbi.nlm.nih.gov/pubmed/25667107
http://dx.doi.org/10.1038/pcan.2015.2

Ejemplares similares